ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026
Recombinant Dabie bandavirus as a bivalent vaccine platform inducing protective immunity against intracellular pathogens and cancer.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne pathogen endemic to East Asia, associated with high mortality and lacking approved vaccines or therapies. We developed a live-attenuated vaccine platform based on a recombinant SFTSV, which lacks the nonstructural protein on the S segment (NSs) gene, a key virulence factor that suppresses type I interferon responses. The resulting ΔNSs viruses, reassorted with the prevalent genotype B, showed attenuated replication in interferon-competent cells while retaining the ability to infect and activate antigen-presenting cells (APCs). Immunization with the ΔNSs virus elicited robust SFTSV-specific humoral and cellular immune responses in mice and non-human primates, conferring complete protection against lethal challenge across multiple SFTSV genotypes, with immunity lasting up to 12 months. Additionally, recombinant ΔNSs viruses encoding heterologous antigens, such as ovalbumin (OVA) or type-specific antigen 56 (TSA56) from Orientia tsutsugamushi, induced strong antigen-specific T cell responses and conferred protection against OVA-expressing melanoma or scrub typhus, respectively. Mechanistically, ΔNSs viruses enhanced APC activation, improved antigen presentation, and reduced apoptosis in infected cells, supporting effective T cell priming. These findings establish SFTSV ΔNSs as an immunogenic and broadly protective vaccine candidate and a versatile bivalent vector platform for targeting viral, intracellular bacterial, and tumor-associated antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.